Moutaz Derbala

Moutaz Derbala

Auto-generated profile, based on publicly available information

Moutaz Derbala

Gastroenterology and Hepatology Department, Hamad Medical Corporation, Doha, Qatar

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 February 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
Yasser FouadYasser Fouad
Yasser Fouad
HGHasmik Ghazinyan
Hasmik Ghazinyan
MAMohamed Alboraie
Mohamed Alboraie
MKMaryam Al Khatry
Maryam Al Khatry
HMHailemichael Mekonnen
Hailemichael Mekonnen
GSGamal Shiha
Gamal Shiha

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MDMoutaz Derbala
Moutaz Derbala
MEMohammed Elshiekh Elbadri
Mohammed Elshiekh Elbadri
AAAliaa Mohamed Amer
Aliaa Mohamed Amer
SASaad AlKaabi
Saad AlKaabi
KSKhaleel Hassan Sultan
Khaleel Hassan Sultan
FSFatma M Shebl
Fatma M Shebl
AIM: To assess the diagnostic accuracy, of aminotransferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection. METHODS: This retrospective study included medical records of three hundred and eighty three Egyptian men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present. RESULTS: Median age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage. CONCLUSION: The study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.

10 January 2026 in Annals of Hepatology
Verified
Journal Article
Open access
Yasser FouadYasser Fouad
Yasser Fouad
REReda Elwakil
Reda Elwakil
FSFaisal M. Sanai
Faisal M. Sanai
OOOlusegun Ojo
Olusegun Ojo
SASameer Al Awadhi
Sameer Al Awadhi
MEMohammed Eslam
Mohammed Eslam
Over the past few decades, the profile of liver diseases in Africa and the Middle East has undergone significant changes. The incidence of metabolic dysfunction-associated fatty liver disease (MAFLD) has risen to alarming levels. Despite the seriousness of the situation, there is a scarcity of local or regional guidelines established to address it. This document presents the clinical practice guidelines from the African Middle East Association of Gastroenterology (AMAGE) related to the screening, diagnosis, and management of MAFLD. It addresses multiple aspects of managing this condition while taking into account local circumstances and the healthcare system's management requirements. These guidelines are intended for routine clinical use, with a specific focus on particular groups when needed. Abbreviations: ALD, Alcoholic liver disease; ALT, Alanine aminotransferase; AMAGE, African Middle East Association of Gastroenterology; AST, Aspartate transaminase; AUC, Area under the curve; BMI, Body mass index; CAP, Controlled attenuation parameter; CKD, Chronic kidney disease; CRN, Clinical Research Network; CSPH, Clinically significant portal hypertension; CT, Computed tomography; CVD, Cardiovascular diseases; DALY, Disability-adjusted life years; EGD, Esophagogastroduodenoscopy; EUS-PPG, Endoscopic ultrasound-derived portal pressure gradient; FIB-4, Fibrosis-4 Index; FLI, Fatty liver index; FLIP, Fatty Liver Inhibition of Progression; GCKR, Glucokinase regulator gene; GRADE, Grading of Recommendation, Assessment, Development, and Evaluation; HCC, Hepatocellular carcinoma; HDL, High-density lipoprotein; HOMA-IR, Homeostasis model assessment of insulin resistance; hsCRP, High-sensitivity C-reactive protein; HSD17B13, Hydroxysteroid 17-beta dehydrogenase 13; HSI, Hepatic steatosis index; HVPG, Hepatic venous pressure gradient; LSM, Liver stiffness measurement; MAFLD, Metabolic dysfunction-associated fatty liver disease; MASH, Metabolic dysfunction-associated steatohepatitis; MBOAT7, Membrane-bound O-acyltransferase domain-containing 7; MENA, Middle East and North Africa; MRE, Magnetic resonance elastography; MRI, Magnetic resonance imaging; MRI-PDFF, Magnetic resonance imaging-proton density fat fraction; MRS, Magnetic resonance spectroscopy; NAFLD, Non-alcoholic fatty liver disease; NAS, NAFLD activity score; NITs, Non-invasive tests; PH, Portal hypertension; PNPLA3, Patatin-like phospholipase domain-containing 3; SAF, Steatosis, activity, fibrosis (score); SSM, Spleen stiffness measurement; T2DM, Type 2 diabetes mellitus; TM6SF2, Transmembrane 6 superfamily member 2; VCTE, Vibration-controlled transient elastography.

13 August 2020 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
ANArun Prabhakaran Nair
Arun Prabhakaran Nair
SSSreethish Sasi
Sreethish Sasi
MAMuna S. Al‐Maslamani
Muna S. Al‐Maslamani
PCPrem Chandra
Prem Chandra
SHSamar A. Hashim
Samar A. Hashim
MDMoutaz Derbala
Moutaz Derbala
Background: The emergence of hepatitis B surface antigen in a patient with previously negative hepatitis B virus (HBV) serology post‐orthotropic liver transplant (OTLX) is known as de novo hepatitis B (DNHB). As there are no data on patients with DNHB available from Qatar, we aim to do a pioneer study indexing their clinical profile and epidemiology of patients with DNHB in Qatar.Materials and Methods: This descriptive epidemiological study was done by retrospectively reviewing records of 159 post‐OTLX patients. HBV serology of these patients post‐OTLX was reviewed, and 17 were identified as DNHB cases. Baseline epidemiological characteristics were defined and compared between DNHB cases and the rest. DNHB cases were analyzed statistically using the chi‐square test and Kaplan‐Meier curve.Results: The majority of the subjects were men (65%) and Qataris (40%). Mean age was 57.4 ± 12.5 years. Bulk of them underwent OTLX in China (44%). The overall incidence of DNHB was 10.7%, with transplants in China having significantly higher incidence than transplants from all other countries. The mortality rate was 23.5% in DNHB cases compared to 2.8% in non‐DNHB. 67% of patients survived at least 64 months after the diagnosis of DNHB. Five‐year survival did not vary significantly between those with DNHB and those without.Conclusion: Orthotropic liver transplant in centers selecting donors liberally without screening for HBV poses the risk of DNHB. We recommend having protective levels of HBs antibodies before OTLX. Prophylactic antiviral treatment should be considered until peri‐operative HBV transmission has been excluded by screening hepatic tissue for HBV DNA.

1 January 2026 in Qatar Medical Journal
Verified
Journal Article
Open access
MDMoataz Derbala
Moataz Derbala
IOIbrahim M. Obeidat
Ibrahim M. Obeidat
RARaya Abualsuod
Raya Abualsuod
MDMahmoud Draidi
Mahmoud Draidi
NSNagah Selim
Nagah Selim
AEAlaa Elkalamawi
Alaa Elkalamawi
Background : Metabolically-dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in populations with metabolic risk factors, and the liver fibrosis stage is the main determinant of long-term outcomes. The Fibrosis-4 (FIB-4) index is widely recommended as a first-line noninvasive test for fibrosis risk stratification; however, its diagnostic performance may vary across populations. Objective : To evaluate the diagnostic performance of the FIB-4 index for detecting advanced liver fibrosis in Qatari residents with MASLD, using liver biopsy as the primary reference standard and FibroScan as a secondary comparator. Methodology : This retrospective, cross-sectional diagnostic accuracy study included adults with MASLD evaluated at Hamad Medical Corporation in Qatar between January 2023 and December 2024. FIB-4 was calculated from routine laboratory parameters, and fibrosis was staged using the METAVIR (Meta-Analysis of Histological Data in Viral Hepatitis) scoring system. It is a histological scoring system used to grade necroinflammatory activity (A0–A3) and stage liver fibrosis (F0–F4). Advanced fibrosis was defined as METAVIR stage ≥F3. Diagnostic performance metrics and the area under the receiver operating characteristic curve (AUROC) were calculated at established cut-offs. Results : A total of 117 patients were included; 74 patients (63.2%) underwent liver biopsy, and 91 patients (77.7%) underwent FibroScan assessment. Advanced fibrosis was present in 21 patients (17.9%) on biopsy. At a FIB-4 cut-off of 1.3, sensitivity and specificity for detecting advanced fibrosis were 66.7% and 67.9%, respectively, compared with liver biopsy, with an overall accuracy of 67.6% and a negative predictive value of 83.7%. The AUROC for FIB-4 was 0.76. Conclusion : FIB-4 can be used as a first-line, accountable screening tool, followed by another confirmatory tool in high-risk patients.